Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review-Reference-Cited by-同舟云学术

Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review

Published:2020-11-09 Issue:2 Volume:106 Page:184-195
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur. J. Haematol.

Author:

Shragai Tamir¹^ORCID,Gatt Moshe²³^ORCID,Lavie Noa⁴,Vaxman Iuliana⁵⁶,Tadmor Tamar⁷⁸^ORCID,Rouvio Ory⁹,Zektser Miri⁹,Horowitz Nethanel⁴,Magen Hila⁶¹⁰,Ballan Mouna¹¹,Suru Celia¹²¹³,Luttwak Efrat¹^ORCID,Levi Shai¹,Ziv‐Baran Tomer⁶,Avivi Irit¹⁶,Cohen Yael C.¹⁶

Affiliation:

1. Tel‐Aviv Sourasky Medical Center Tel‐Aviv Israel

2. Hadassah Medical Center Jerusalem Israel

3. Hadassah Medical School Hebrew University Jerusalem Israel

4. Rambam Health Care Campus Haifa Israel

5. Rabin Medical Center Petah‐Tikvah Israel

6. Sackler Faculty of Medicine Tel‐Aviv University Tel‐Aviv Israel

7. Hematology Unit Bnai‐Zion Medical Center Haifa Israel

8. The Ruth and Bruce Rappaport Faculty of Medicine Technion Haifa Israel

9. Soroka University Medical Center Beer‐Sheva Israel

10. Hematology Chaim Sheba Medical Center Ramat‐Gan Israel

11. Carmel Medical Center Haifa Israel

12. Galilee Medical Center Naharyia Israel

13. Azrieli Faculty of Medicine Bar Ilan University Ramat Gan Israel

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13535

Reference37 articles.

1. AL amyloidosis: from molecular mechanisms to targeted therapies

2. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment

3. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria

4. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

5. DimopoulosMA WhiteD BenboubkerL et al.Daratumumab lenalidomide and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Updated Efficacy And Safety Analysis Of POLLUX*.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime;British Journal of Haematology;2024-06-05

2. Case report: Light-chain amyloidosis responsive to selinexor in combination with daratumumab and dexamethasone (SDd) therapy;Frontiers in Medicine;2024-05-02

3. Immune Therapies in AL Amyloidosis—A Glimpse to the Future;Cancers;2024-04-22

4. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation;Bone Marrow Transplantation;2023-12-26

5. Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis;Therapeutics and Clinical Risk Management;2023-12